CA2264250C - Tablet with controlled release of alfuzosin hydrochloride - Google Patents
Tablet with controlled release of alfuzosin hydrochloride Download PDFInfo
- Publication number
- CA2264250C CA2264250C CA002264250A CA2264250A CA2264250C CA 2264250 C CA2264250 C CA 2264250C CA 002264250 A CA002264250 A CA 002264250A CA 2264250 A CA2264250 A CA 2264250A CA 2264250 C CA2264250 C CA 2264250C
- Authority
- CA
- Canada
- Prior art keywords
- layer
- tablet according
- tablet
- alfuzosin hydrochloride
- layers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Pharmaceutical tablet intended for the oral route, for the controlled release of alfuzosin hydrochloride into the proximal segments of the gastrointestinal tract, this tablet being characterized in that it consists of:
a) a first layer 1 having the property of swelling considerably and quickly on contact with aqueous biological fluids, the said layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers constituting from 5.0 to 90% and preferably from 10 to 85% of the weight of the layer, b) a second layer 2 adjacent to the first layer, in which the alfuzosin hydrochloride is conveyed, this layer being formulated with hydrophilic polymers and with other auxiliary substances, in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period, c) and optionally a third layer 3 obtained by compression and applied to the layer 2, generally consisting in particular of hydrophilic polymers which gel and/or swell and which may then optionally be broken down and having a barrier function which modifies the release of the alfuzosin hydrochloride from the layer 2, the layer 3 being primarily highly impervious to passage of the active substance.
a) a first layer 1 having the property of swelling considerably and quickly on contact with aqueous biological fluids, the said layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers constituting from 5.0 to 90% and preferably from 10 to 85% of the weight of the layer, b) a second layer 2 adjacent to the first layer, in which the alfuzosin hydrochloride is conveyed, this layer being formulated with hydrophilic polymers and with other auxiliary substances, in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period, c) and optionally a third layer 3 obtained by compression and applied to the layer 2, generally consisting in particular of hydrophilic polymers which gel and/or swell and which may then optionally be broken down and having a barrier function which modifies the release of the alfuzosin hydrochloride from the layer 2, the layer 3 being primarily highly impervious to passage of the active substance.
Description
10152025CA 02264250 l999-02- 191TABLET WITH CONTROLLED RELEASE OF ALFUZOSINHYDROCHLORIDEThe present invention relates to a tabletwith controlled release of alfuzosin hydrochloride andto a pharmaceutical composition containing one or moretablets.Alfuzosin hydrochloride is an activesubstance that is known in the treatment of benignhypertrophy of the prostate. There is a wealth of dataand experimental studies regarding the activity of theproduct. In particular, there is a large amount of dataregarding the bioavailability of the product and thepharmacokinetics of the active substance. Indeed, it isan active substance which has a relatively short half-life and a more intense absorption at the duodenum-jejunum level, but the size of which decreases alongthe intestinal tract. Consequently, for an optimumeffect, the administration of alfuzosin hydrochlorideas conventional tablets (with rapid disintegration anddissolution) must be carried out several times a day.For these reasons, alfuzosin hydrochloride is acandidate for the production of a pharmaceuticalpreparation with controlled release in the promixalupper parts of the tract (duodenum and jejunum).In the pharmaceutical field, noteworthyprogress has been made in recent years in theproduction of increasingly improved systems for thel0152025CA 02264250 l999-02- 192release of active substances, which are capable ofreleasing the active substances conveyed per seaccording to kinetics and modes of release designed toallow optimum therapeutic effects.Prolonged-release forms (or delayed-effectpreparations) are characterized in that they convey amarkedly larger amount of medicinal product thantraditional pharmaceutical preparations, so as to allowthe dosage to be simplified. That is to say that theadministration decreases from two, three or more timesa day to only one administration of a pharmaceuticalpreparation (or therapeutic system) capable ofproviding satisfactory therapeutic cover throughout theday.Preparations of this type have been used andmarketed for a long time, among which mention should bemade of: chronoids, microcapsules and microâmatrices,tablets generically defined as "delayed-effectâtablets, gastroâresistent tablets and more complexpreparations such as hydrophilic matrices which breakdown and/or swell. Recently, more refined therapeuticsystems have been produced, for example soâcalled"reservoir" systems and the Geomatrixc systems asdescribed in US patents 4,839,177 and 5,422,123.Most of these novel therapeutic systems arecapable of releasing the active substance conveyed perse,at a constant rate (that is to say according tozero-order kinetics) up to complete release of the10152025CA 02264250 2004-01-123active substance, independently of the pH conditions ofthe gastrointestinal tract, and thus uniformly alongthe gastrointestinal tract. It results therefrom thatthese systems may be applied widely in the case ofadministration of medicinal products that are absorbeduniformly in the gastrointestinal tract. However, thesepharmaceutical systems may have major drawbacks in thecase where active substances per se would be conveyed,such as alfuzosin, having a more intense absorption atthe duodenum-jejunum level which decreases thereafterin the tract. Indeed, in this case, only a very limitedamount of the active substance conveyed may be absorbedand thus exert the desired therapeutic activity,whereas most of the medicinal product released by thepharmaceutical preparation cannot be absorbed since, inlower portions of the gastrointestinal tract, thebiological barriers are relatively incapable ofallowing the medicinal product to pass.The subject of the present patent applicationis a tablet with controlled release of alfuzosinhydrochloride, which overcomes the drawbacks mentionedabove.The invention consists of a pharmaceuticaltablet intended for the oral route, for the controlledrelease of alfuzosin hydrochloride into the proximalsegments of the gastrointestinal tract, this tablet beingcharacterized in that it consists of:a) a first layer having the property of101520CA 02264250 2004-01-12swelling 1.5 times relative to the initial volume after2 hours on contact with aqueous biological fluids, the layerbeing produced by compression of a mixture or of a granulatecomprising hydrophilic polymers constituting from 5.0 to 90%of the weight of the layer,b) a second layer adjacent to the first layer,in which the alfuzosin hydrochloride is conveyed, this layerbeing formulated with hydrophilic polymers and with otherauxiliary substances, in order to give the preparationsuitable properties of compressibility and in order to allowthe release of alfuzosin hydrochloride within apredetermined time period,c) and optionally a third layer obtained bycompression and applied to the second layer, comprisinghydrophilic polymers which are chosen from the groupconsisting of hydroxymethylcellulose, hydroxyethylcellulose,hydroxypropylmethylcellulose having a molecular weight offrom 1000 to 4,000,000, hydroxypropylcellulose having amolecular weight of from 2000 to 2,000,000,carboxyvinylpolymers, chitosans, mannans, galactomannans, xanthans,carrageenans, amylose, alginic acid, its salts and itsderivatives, pectins, acrylates, methacrylates, acrylic/methacrylic copolymers, polyanhydrides, polyamino acids,poly (methyl vinyl ether/maleic anhydride) polymers,10CA 02264250 2004-01-12polyvinyl alcohols, glucans, scleroglucans,carboxymethylcellulose, ethylcellulose and methylcellulose.The invention is characterized in that oncontact with gastric juices, after rapid andconsiderable swelling of at least one of the layers 1or 3, as well as by the possible swelling of the layer2, the pharmaceutical preparation increasesconsiderably in volume; thus, the pharmaceuticalpreparation remains in the stomach for longer. In thisway, most of the alfuzosin hydrochloride contained may10152025...... -.«n ,..u.CA 02264250 l999-02- 19Sbe absorbed in a controlled manner in that portion ofthe gastrointestinal tract which has the highestcapacity for absorption.The layers 1 and 3 may have an identicalcomposition and identical functional properties or theymay have a different composition and differentproperties.when the layers 1 and 3 have identicalfunctional properties and compositions, they may differby their amounts and their thicknesses applied to thelayer 2.At least one of the layers 1 and 3 acts as abarrier, that is to say that it is primarily highlyimpervious to passage of the alfuzosin hydrochloridecontained in the layer 2 and at least one of the layersis characterized in that it swells quickly, that is tosay that it quickly increases in volume.Another embodiment of the pharmaceuticalpreparation is characterized in that the tabletcontaining 3 layers is formed of a first layer 1 asdescribed above, that is to say that its sole functionis to increase considerably in volume on contact withaqueous liquids, a second layer 2 conveying some of thealfuzosin hydrochloride which has to be released withina predetermined time period, and a third layer 3 inwhich some of the alfuzosin hydrochloride is conveyed,formulated such that it can be released immediately oncontact with gastric juices.10152025CA 02264250 l999-02- 196The amount of alfuzosin hydrochloride carriedin the tablet is between 2.5 and 50 mg.The polymeric substances which are used inthe layers 1 and 3, and which may also be used in thelayer 2, are biocompatible and have hydrophilicproperties. They are slowly soluble and/or slowlygelable and/or swell rapidly or at a different rate inaqueous liquids and then may optionally be broken down;they are chosen from the following group:hydroxymethylcellulose, hydroxyethyl-cellulose, hydroxypropylmethylcellulose having amolecular weight of from 1000 to 4,000,000,hydroxypropylcellulose having a molecular weight offrom 2000 to 2,000,000, carboxyvinyl polymers,chitosans, mannans, galactomannans, xanthans,carrageenans, amylose, alginic acid, its salts and itsderivatives, pectins, acrylates, methacrylates,acrylic/methacrylic copolymers, polyanhydrides,polyamino acids, poly(methyl vinyl ether/maleicanhydride) polymers, polyvinyl alcohols, glucans,scleroglucans, carboxymethylcellulose and itsderivatives, ethylcellulose, methylcellulose and, ingeneral, hydrophilic cellulose derivatives.The content of hydrophilic polymers may rangefrom 5 to 90% relative to the total weight of thelayer, but preferably from 10 to 85% and moreparticularly from 20 to 80%.In order to promote a rapid and considerableO10152025CA 02264250 2004-01-127increase in the volume of the pharmaceuticalpreparation, during the preparation of the layers 1 and3, with the hydrophilic polymers mentioned above, it ispossible to use hydrophilic products and/or excipientscapable of promoting wetting of the layers, in this wayfacilitating interaction between the components of thesaid layer and the biological fluids with which thelayer comes into contact. These hydrophilic excipientsare preferably chosen from the groups of so-calledâsuper disintegrating" excipients comprisingcrosslinked polyvinylpyrrolidone, hydroxypropylcelluloseand hydroxypropylmethylcellulose having amolecular weight of 1,000 to 1,000,000 crosslinkedsodium carboxymethylcellulose, carboxymethyl starch andits salts, and divinylbenzene/potassium methacrylatecopolymer.These substances constitute from 1 to 50% ofthe weight of the layer and preferably from 10 to 30%.It is moreover possible also to usesurfactants (anionic, cationic and nonionicsurfactants) which, by facilitating wetting, allow amore rapid interaction between the dissolution medium(or gastric fluid) and the tablet, thereby allowingmuch faster wetting and swelling of the pharmaceuticalpreparation, preferably of the layer in which thishydration-modifying component is conveyed. In the groupof substances possessing these properties, mention maybe made of products such as sodium lauryl sulphate,10152025CA 02264250 l999-02- 198sodium ricinoleate, sodium tetradecyl sulphate, sodiumdioctyl sulphosuccinate, cetomagrogol, poloxamer,glyceryl monostearate, polysorbates, sorbitanmonolaurate, lecithins or any other pharmaceuticallyacceptable surfactant.In addition, other hydration-modifyingelements may be used, these being chosen from thefollowing group of substances:â hydrophilic diluents such as mannitol,lactose, starches of various origins, sorbitol,xylitol, microcrystalline cellulose and/or substanceswhich, in general, promote the penetration of water orof aqueous fluids into the pharmaceutical preparation,- hydrophobic diluents such as glycerylmonostearate, palmitates, hydrogenated orunhydrogenated plant oils such as hydrogenated castoroil, waxes, mono-, di- or trisubstituted glycerides,for slowing down the penetration of water or of aqueousfluids into the pharmaceutical preparation.The technical preparation of the tablets maylead to introducing:- lubricants such as magnesium stearate,stearic acid, glyceryl monostearate, polyoxyethyleneglycols having a molecular weight of from 400 to7,000,000, hydrogenated Castor oil, glyceryl behenate,mono-, di- or trisubstituted glycerides,â flow agents such as colloidal silica orany other silica,10152025CA 02264250 l999-02- 199- and binders, buffers, absorbing agents,as well as any other pharmaceutically acceptableadditive.The tablets of the invention may be producedin the following way: powders and/or granulates aremixed using current production technologies and thuswith a production process which may be industrializedimediately.The pharmaceutical tablet containing two orthree layers is obtained according to tabletingprocesses that are very comonly used and known tothose skilled in the art.For example, the tablets may be producedusing rotary presses capable of producing "multi-layer"tablets.Normally, the working compression forceranges from 7 to 50 KN (or kilonewtons) and, accordingto the processes which will be described in greaterdetail in the examples, tablets containing two or threelayers having a cylindrical, lenticular, spheroidal orovoid shape which makes them easy to administer and toswallow, are obtained.Depending on the amount of active substancewhich is conveyed, each layer of the tablet may have adifferent thickness ranging from 0.2 to 8 mm, butpreferably from 1 mm to 4 mm.A coating made of polymer materials, whoseaim is to afford simple protection or alternatively a10152025CA 02264250 l999-02- 1910slowing-down at the start of the release of the activesubstance conveyed in the pharmaceutical preparation,may also be applied to this pharmaceutical prepartion.The coating may be soluble in acidic solution oralternatively permeable, so as to allow activation ofthe tablet (release of the active substance) only aftera predetermined time period.According to another embodiment of theinvention, a soluble coating containing alfuzosinhydrochloride may be applied so as to allow immediaterelease of some of the active substance on contact withthe gastric juices.The coating may be applied by standardmethods known to those skilled in the art using organicor aqueous solutions.Figure 1 presents an embodiment of theinvention comprising a tablet with three layers asdescribed above.on contact with gastric juices and/or fluidsof the gastrointestinal tract, the tablet rapidlyincreases in volume, taking the structure shown inFigure 2.This increase in volume may be determined andlimited to a single layer or to several layers of thetablet; this increase in volume, as well as the rate atwhich this phenomenon takes place, may be monitored andevaluated precisely by direct measurement or by a videomicroscope coupled to a computer. The measurement is10152025CA 02264250 l999-02- 1911performed by a special video analysis programme.The tablet is characterized in that thevolume of at least one of the layers increases, at theend of 2 hours, by 1.5 times and preferably by at least3 times relative to the initial volume.By this method, it is possible to study thebehaviour "in vitro" of various preparations (describedin the examples of the Application) and thus to designpharmaceutical preparations capable of satisfying therequired morphological qualities, as well as ofoptimizing the preparation of each of the said layersso as to obtain the morphological behaviour whichsatisfies the requested aim. This type of analysis thusmakes it possible to model the "in vivo' behaviour ofthe pharmaceutical preparation on contact withbiological fluids. It is also possible to program,within a determined time period, the release of theactive substance conveyed in the pharmaceuticalpreparation.The pharmaceutical compositions of thepresent invention may be in the form of tablets orsmall tablets or gelatin capsules comprising smalltablets.At least two small tablets may also becombined in the same pharmaceutical composition. Theymay be packaged in a common envelope, for example in awafer capsule or in a gelatin capsule.when the pharmaceutical composition consists101520CA 02264250 l999-02- 1912of small tablets, each of these may have a different oridentical composition.The examples which follow are intended toillustrate the invention.Exam le 1:Preparation of a series of tablets (5000)based on alfuzosin hydrochloride.;_g: Preparation of the granulate containing the activesubstanceA granulate is prepared, according to theprocess described below, which is used for thepreparation of the layer 2 of Figure 1 containing10.0 mg of alfuzosin hydrochloride and having thefollowing unit composition:Alfuzosin hydrochloride 10.00 mgMannitol 10.00 mgHydroxypropylmethylcellulose USP 2208 10.00 mgPolyvinylpyrrolidone 3.20 mgMicrocrystalline cellulose 65.00 mgMagnesium stearate 1.00 mgColloidal silica 1.25 mgTotal 100.45 mgThe manufacturing process consists inpreparing a granulate by mixing together the amounts of101520CA 02264250 l999-02- 1913active substance required, mannitol, microcrystallinecellulose and hydroxypropylmethylcellulose. The uniformpowder mixture is moistened uniformly with an alcoholicsolution based on 10% w/v polyvinyl-pyrrolidone and isthen dried to a predetermined percentage of residualmoisture in a fluidized-air bed at 40â45°C. The driedgranulate is calibrated and placed in a powder mixerwith magnesium stearate and colloidal silica and it isthen mixed until homogeneous.;_§: Preparation of the granulate constituting layer 1which swellsAn amount of granulate required to obtain5000 layers which swell, layer 1 of Figure 1, wereprepared, each layer having the following percentagecomposition:Hydroxypropylmethylcellulose 79.75%Hydrogenated castor oil 13.50%Yellow iron oxide 0.25%Ethylcellulose 5.00%Magnesium stearate 1.00%Silica gel 0.50%Total 100.00%The manufacturing process consists of thepreparation of a granulate obtained by mixing the101520CA 02264250 l999-02- 1914required amounts of hydroxypropylmethylcellulose,hydrogenated castor oil and iron oxide; the uniformpowder mixture is moistened with an alcoholic solutionbased on 10% w/v ethylcellulose and the uniformlymoistened mass is dried in a fluidizedâair bed at 40-45°C. The granulate, dried to a predeterminedpercentage of moisture, is calibrated and placed in apowder mixer with magnesium stearate and colloidalsilica and it is mixed until homogeneous.;_§: Preparation of the granulate constituting thethird layer 3 which acts as a barrierAn amount of granulate required to obtain5000 barrier layers is prepared, layer 3 of Figure 1,each layer having the following percentage composition:Hydroxypropylmethylcellulose 76.00%Hydrogenated castor oil 18.60%Polyvinylpyrrolidone 3.15%Yellow iron oxide 0.10%Magnesium stearate 0.70%Colloidal silica 1.45%Total 100.00%The manufacturing process consists in mixingthe required amounts of hydroxypropylmethylcellulose,hydrogenated Castor oil and yellow iron oxide; the10152025CA 02264250 l999-02- 1915homogeneous powder mixture is moistened with a solutionbased on 10% w/v polyvinylpyrrolidone in ethanol andthe wet mass is dried in a fluidized-air bed at 40-4S°C. The granulate, dried to a predeterminedpercentage of residual moisture, is calibrated andplaced in a powder mixer with magnesium stearate andcolloidal silica and mixed until homogeneous.;_Q: Preparation of tablets containing three layers (bycompression)The granulates obtained are loaded into thethree supply hoppers of a rotary multi-layer presscapable of producing three-layer tablets. The granulatedescribed in point 1 B is loaded into the first hopper,the granulate according to the description of point 1 Ais loaded into the second hopper and the granulateaccording to the description of point 1 C is loadedinto the third hopper; granulates 1 B and 1 C may beinverted in the hoppers.The multi-layer press is equipped with flatcircular bevelled punches having a diameter of 8 mm.The machine is adjusted to produce three-layer tabletsconsisting of a first amount of 100 mg of layer 1 for athickness of about 1.7 mm, a second amount of 100.45 mgof granulate containing the active substance(equivalent to 10.0 mg of alfuzosin hydrochloride) anda third amount of 150 mg of layer 3 for a thickness ofabout 3.3 mm. Working according to the above10152025CA 02264250 l999-02- 1916description, three-layer tablets having an averageweight of 350.45 mg and containing 10.0 mg of alfuzosinhydrochloride are produced.;_§: Dissolution testIn order to evaluate the release propertiesof the complete tablets, the vane machine (described inUSP XXIII) is used, working at 100 rpm and using asdissolution liquid a 0.01 M HCl solution at 37°C. Therelease of the active substance is monitored by UVspectrophotometric determination at 330 nm using asampling and automatic reading system.The results of the tests carried out aregiven in Table 1.TABLE 1Time (hours) % released1 16.02 25.03 32.04 37.06 48 08 57.010 66.012 74.016 88.020 95.0CA 02264250 l999-02- 191724 98.0A controlled release of the active substanceis obtained in about 20 hours.;_§: Swelling test5 The test is carried out under the sameexperimental conditions as the dissolution test. Thetablets are taken from the dissolution medium atregular intervals and their volume and the sizes of thevarious layers are measured with a video-microscope10 coupled to an image-analysis system. The results of thetests carried out are given in Table 2.101520CA 02264250 l999-02- 1918TABLE 2Swelling time Volume (layer 2 Volume of layer 1(hours) + layer 3) (%)(%)0 100.0 100.00.5 142.0 211.11 152.7 271.01.5 175.2 302.62 161.8 399.53 182.7 483.74 196.0 534.05 199.4 609.86 V 195.7 727.97 166.8 809.98 138.9 851.010 139.9 937.5It may be noted that, in the tablets, layer 1increases considerably in volume, up to 9 times itsinitial volume. This phenomenon is very evident if itis related to the increase in volume of the other twolayers, layer 2 and layer 3, which cumulatively swellto about 2-fold. In addition, layer 1 increases involume at a rate which is considerably higher than thatof the other layers.101520CA 02264250 l999-02- 1919Exam le 2Preparation of a series of tablets (10,000)as reported in Figures 1 and 2, containing alfuzosinhydrochloride as active substance.g_g:Preparation of the granulate containing the activesubstanceA granulate is prepared, according to theprocess described in Example 1 A, which is used in thepreparation of the layer 2 of Figure 1 containing7.5 mg of alfuzosin hydrochloride, and having thefollowing unit composition:Alfuzosin hydrochloride7.50 mgMannitol 10.00 mgHydroxypropylmetbylcellulose 10.00 mgPolyvinylpyrrolidone 3.20 mgMicrocrystalline cellulose 65.00 mgMagnesium stearate 1.00 mgColloidal silica 1.25 mgTotal 97.95 mg2 B: Preparation of the granulate constituting thefirst layer 1 which swellsAn amount of granulate required to obtain10,000 layers which swell, layer 1 of Figure 1, isprepared according to the process described in Example101520CA 02264250 l999-02- 19201B, each layer having the followingcomposition:percentage unitHydroxypropylmethylcellulose 79.75%Hydrogenated castor oil 13.50%Ethylcellulose 5.00%Iron oxide 0.25%Magnesium stearate 1.00%Colloidal silica 0.50%Total 100.00%2 C: Preparation of the granulate constituting thethird layer 3An amount of granulate required to obtain10,000 barrier layers,according to the process described in Example 1C,layer having the following percentagelayer 3 of Figure 1,is preparedeachunit composition:HydroxypropylmethylcelluloseHydrogenated castor oilPolyvinylpyrrolidoneYellow iron oxideMagnesium stearateColloidal silica76.00%18.60%3.15%0.10%1.45%Total100.00%10152025CA 02264250 l999-02- 1921g_Q: Preparation of the threeâlayer tablets (bycompression)The granulates obtained according to Examples2 A, 2 B and 2 C are loaded into the three supplyhoppers of a rotary press with respective amounts of100 mg of granulate for layer 1 for a thickness of1.75 m, 97.95 mg of granulate containing the activesubstance (corresponding to 7.5 mg of alfuzosinhydrochloride) for layer 2 and 150 mg for layer 3 for athickness of 3.3 m. By working in the manner describedabove, three-layer tablets having an average weight of347.95 mg and containing 7.5 mg of active substance areobtained.2 E: Dissolution testThe dissolution tests are carried outaccording to the process described in Example 1 E.The results are given in Table 3.TABLE 3Time (hours) % released1 15.12 24.44 37.76 48.08 57.610 - 66.0CA 02264250 l999-02- 19121416182274.282.289.194.898.6It may be noted that the controlled releaseof the active substance takes place over about 20hours.2 F: Swelling test10 The swelling tests are carried out accordingto the process described in Example 1 F. The resultsare given in Table 4.Time (hours)TABLE 4Volume (layer 2Volume of layer 1+ layer 3) (%)(%)15 0 100.0 100.00.5 137.6 233.21 142.3 305.11.5 150.4 338.52 142.3 412.420 3 167.1 435.2101520CA 02264250 l999-02- 19234 139.2 526.56 132.0 665.08 129.9 715.1It may be noted that in the tablets prepared,the volume of layer 1 increases considerably, by up to7 times the initial volume; layer 2 and layer 3increase by up to one and a half times. In addition,layer 1 increases in volume at a rate which is verymuch higher than that of the other two layers.Example 3: Preparation of a series of tablets(10,000) containing alfuzosin hydrochloride as activesubstance§_§: Preparation of the granulate containing the activesubstance.A granulate used in the preparation of layer2 is prepared according to the process described inExample 1 A, this granulate containing 10.0 mg ofalfuzosin hydrochloride and having the following unitcomposition:Alfuzosin hydrochloride 10.00 mgMannitol 10.00 mgHydroxypropylmethylcellulose 10.00 mgPolyvinylpyrrolidone 3.20 mg101520CA 02264250 l999-02- 1924Microcrystalline cellulose 65.00 mgMagnesium stearate 1.00 mgColloidal silica 1.25 mgTotal 100.45 mg3 B: Preparation of the granulate constituting thefirst layer 1 which swellsAn amount of granulate required to obtain10,000 layers which swell, layer 1 of Figure 1, isprepared according to the process described,having the following percentage composition:each layerHydroxypropylmethylcellulose 75.00%Glyceryl behenate 13.40%Polyvinylpyrrolidone 5.00%Iron oxide 0.10%Polyvinylpyrrolidone 5.00%Magnesium stearate 1.00%Colloidal silica 0.50%Total 100.00%3 C: Preparation of the granulate constituting thethird layer 3An amount of granulate required to obtain10,000 layers, layer 3 of Figure 1, is preparedaccording to the process described in Example 1 C,each101520CA 02264250 l999-02- 1925layer having the following percentage composition:Hydroxypropylmethylcellulose 76.00%Hydrogenated castor oil 18.60%Polyvinylpyrrolidone 3.15%Yellow iron oxide 0.10%Magnesium stearate 1.45%Colloidal silica 0.70%Total 100.00%;_Q: Preparation of three-layer tablets (bycompression)The granulates obtained as described inExamples 3 A, 3 B and 3 C are loaded into the threesupply hoppers of a rotary press with respectiveamounts of 100 mg of granulate for layer 1, 100.45 mgof granulate containing the active substance for layer2 and 150 mg for layer 3. By working in the mannerdescribed above, three-layer tablets having an averageweight of 350.45 mg and containing 10.0 mg of activesubstance are obtained.;_§: Dissolution testThe dissolution tests are carried outaccording to the process described in Example 1 E.The results of the tests carried out aregiven in Table 5... .-.@ 101520Time (hours)CA02264250 1999-02-1926TABLE 5% released10121416182019.027.841.753.464.775.684.690.995.197.899.4substance takes place over about 18 hours.3___._.to the process described in Example 1 F.Swelling testgiven in Table 6.The controlled release of the activeThe results of the tests carried out areThe swelling tests are carried out accordingCA 02264250 l999-02- 1927TABLE 6Time (hours) Volume (layer 2 Volume of layer 1+ layer 3) (%)(%)0 100.0 100.00.5 124.0 231.85 1 130.5 297.02 108.5 387.03 115.2 448.84 131.3 517.25 124.7 554.510 6 137.0 601.18 106.6 740.5It may be noted that in the tablets prepared,the volume of layer 1 which swells increasesconsiderably, by up to 7 times its initial volume;15 layer 2 and layer 3 only increase by 30-40% relative tothe initial volume. In addition, the layer which swellsincreases in volume at a rate which is very much higherthan that of the other two layers.101520CA 02264250 l999-02- 1928Example 4: Preparation of a series of tablets(5000) based on alfuzosin hydrochloride.g_g: Preparation of the granulate containing the activesubstanceA granulate is prepared according to theprocess described below, which is used for thepreparation of layer 2 of Figure 1 containing 10.0 mgof alfuzosin hydrochloride and having the followingunit composition:Alfuzosin hydrochloride 10.00 mgLactose 60.30 mgHydroxypropylmethylcellulose USP 2208 25.00 mgPolyvinylpyrrolidone 3.20 mgMagnesium stearate 1.00 mgColloidal silica 0.50 mgTotal 100.00 mgThe manufacturing process consists inpreparing a granulate by mixing the required amounts ofactive substance, of lactose, of polyvinylpyrrolidoneand of hydroxypropylmethylcellulose. The uniform powdermixture is uniformly moistened with purified water andis then dried to a predetermined residual moisturepercentage in a fluidizedâair bed at 40â45°C. The driedgranulate is calibrated and placed in a powder mixer. wâ »..101520CA 02264250 l999-02- 1929with magnesium stearate and colloidal silica and isthen mixed until homogeneous.g_§: Preparation of the granulate constituting layers 1and 3 which swell and form a barrierAn amount of granulate required to obtain10,000 layers which swell and form a barrier, layers 1and 3 of Figure 1, is prepared, each layer having thefollowing percentage composition:Hydroxypropylmethylcellulose USP 2208 40.00%Lactose 39.75%Glyceryl behenate 13.50%Yellow iron oxide 0.25%Polyvinylpyrrolidone 5.00%Magnesium stearate 1.00%Colloidal silica 0.50%Total 100.00%The manufacturing process consists inpreparing a granulate obtained by mixing together therequired amounts of hydroxypropylmethylcellulose, oflactose, of glyceryl behenate, of polyvinylpyrrolidoneand of iron oxide; the uniform powder mixture ismoistened with purified water. The uniformly moistenedmass is dried in a fluidized-air bed at 40â45°C. Thegranulate, dried to a predetermined moisture10152025CA 02264250 l999-02- 1930percentage, is calibrated and placed in a powder mixerwith magnesium stearate and colloidal silica and it ismixed until homogeneous.g_g: Preparation of three-layer tablets (bycompression)The granulates obtained are loaded into thethree supply hoppers of a rotary multilayer presscapable of producing three-layer tablets. The granulatedescribed in point 4 B is loaded into the first andthird hoppers; the granulate according to thedescription of point 4 A is loaded into the secondhopper.The multi-layer press is equipped with flatcircular bevelled punches having a diameter of 8 mm.The machine is adjusted to produce three-layer tabletsconsisting of a first amount of 100 mg of layer 1 or 3for a thickness of about 1.7 mm, a second amount of100 mg of granulate containing the active substance anda third amount of 100 mg of layer 1 or 3 for athickness of about 1.7 m. By working according to theabove description, threeâlayer tablets having anaverage weight of 300 mg and containing 10.0 mg ofalfuzosin hydrochloride are produced.Example 5Preparation of a series of tablets (5000) based onalfuzosin hydrochloride.101520CA 02264250 l999-02- 1931§_§: Preparation of the granulate containing the activesubstanceA granulate is prepared according to theprocess described in Example 4 A, this granulate beingused in the preparation of layer 2 of Figure 1containing 15 mg of alfuzosin hydrochloride and havingthe following unit composition:Alfuzosin hydrochloride 15.00 mgLactose 55.30 mgHydroxypropylmethylcellulose USP 2208 25.00 mgPolyvinylpyrrolidone 3.20 mgMagnesium stearate 1.00 mgColloidal silica 0.50 mgTotal 100.00 mg§_§: Preparation of the granulate constituting layers 1and 3 which swell and form a barrierAn amount of granulate required to obtain10,000 layers which swell and form a barrier, layers 1and 3 of Figure 1, is prepared, each layercorresponding to the composition and to themanufacturing process described in Example 4 B.5 C: Preparation of three-layer tablets (bycompression)By working in the manner described above. _........._...awâ-u.u..........._. 101520CA 02264250 l999-02- 1932(Example 4 C), three-layer tablets containing 15.0 mgof active substance are obtained with the granulatesdescribed in Examples 5 A and 5 B.Exam le 6Preparation of a series of tablets (5000) based onalfuzosin hydrochloride.§_A: Preparation of the granulate containing the activesubstanceA granulate is prepared according to theprocess described below, this granulate being used inthe preparation of layer 2 of Figure 1 containing 10 mgof alfuzosin hydrochloride and having the followingunit composition:Alfuzosin hydrochloride 10.00 mgMicrocrystalline cellulose 33.80 mgMannitol 10.00 mgHydroxypropylmethylcellulose USP 2208 40.00 mgPolyvinylpyrrolidone 5.00 mgMagnesium stearate 1.00 mgColloidal silica 0.20 mgTotal 100.00 mgThe manufacturing process consists inpreparing a granulate by mixing together the required101520CA 02264250 l999-02- 1933amounts of active substance, of cellulose, ofpolyvinylpyrrolidone, of mannitol and ofhydroxypropylmethylcellulose. The uniform powdermixture is moistened uniformly with purified water andis then dried to a predetermined residual moisturepercentage in a fluidized-air bed at 40-50°C. The driedgranulate is calibrated and placed in a powder mixerwith magnesium stearate and colloidal silica untilhomogeneous..§_§: Preparation of the granulate constituting layers 1and 3 which swell and form a barrierAn amount of granulate required to obtain10,000 layers which swell and form a barrier, layers 1and 3 of Figure 1, is prepared, each layer having thefollowing percentage composition:Hydroxypropylmethylcellulose USP 2208 45.00%Lactose 28.60%Microcrystalline cellulose 20.00%Yellow iron oxide 0.20%Polyvinylpyrrolidone 5.00%Magnesium stearate 1.00%Colloidal silica 0.20%Total 100.00%The manufacturing process is identical to101520CA 02264250 l999-02- 1934that of Example 4 B, the microcrystalline cellulosebeing added in place of the glyceryl behenate.§_Q: Preparation of three-layer tablets (bycompression)By working in the manner described above(Example 4 C), three-layer tablets containing 10.0 mgof active substance are obtained with 100 mg, for eachof the layers, of granulates described in Examples 6 Aand 6 8, layers 1 and 3 having a thickness of about1.8 mm.Example 7Preparation of a series of tablets (5000) based onalfuzosin hydrochloride.1_A: Preparation of the granulate containing the activesubstanceA granulate is prepared according to theprocess described below, this granulate being used inthe preparation of layer 2 of Figure 1 containing 15 mgof alfuzosin hydrochloride and having the followingunti composition:Alfuzosin hydrochloride 15.00 mgMicrocrystalline cellulose 28.80 mgMannitol 10.00 mgHydroxypropylmethylcellulose USP 2208 40.00 mg...._._ââ-ââ..._....«-CA 02264250 l999-02- 1935Polyvinylpyrrolidone 5.00 mgMagnesium stearate 1.00 mgColloidal silica 0.20 mgTotal 100.00 mg5 The manufacturing process is identical tothat of Example 6 A.7 B: Preparation of the granulate constituting layers 1and 3 which swell and form a barrierAn amount of granulate required to obtain10 10,000 layers which swell and form a barrier, layers 1and 3 of Figure 1, is prepared, each layercorresponding to the composition and to themanufacturing process described in Example 6 B.7 C: Preparation of three-layer tablets (by15 compression)By working in the manner described above(Example 6 C), threeâ1ayer tablets containing 15.0 mgof active substance are obtained with the granulatesdescribed in Examples 7 A and 7 B.101520CA 02264250 l999-02- 1936Example 8Preparation of a series of tablets (5000) based onalfuzosin hydrochloride.§_A: Preparation of the granulate containing the activesubstanceA granulate is prepared, which is used in thepreparation of layer 2 of Figure 1, containing 10 mg ofalfuzosin hydrochloride, with a composition identicalto that described in Example 6 A and according to thesame PIOCESS .§_§: Preparation of the granulate constituting layers 1and 3 which swell and form a barrierAn amount of granulate required to obtain10,000 layers which swell and form a barrier, layers 1and 3 of Figure 1, is prepared, each layer having thefollowing percentage composition:Hydroxypropylmethylcellulose USP 2208 35.00%Lactose 34.50%Microcrystalline cellulose 23.90%Yellow iron oxide 0.40%Polyvinylpyrrolidone 5.00%Magnesium stearate 1.00%Colloidal silica 0.20%Total 100.00%101520CA 02264250 l999-02- 1937The manufacturing process is identical tothat of Example 6 B.§_g: Preparation of three-layer tablets (bycompression)The granulates obtained are loaded into thethree supply hoppers of a rotary multiâlayer presscapable of producing three-layer tablets. The granulatedescribed in point 8 B is loaded into the first andthird hoppers; the granulate according to thedescription of point 8 A is loaded into the secondhopper.The multi-layer press is equipped with flatcircular bevelled punches having a diameter of 8 mm.The machine is adjusted to produce three-layer tabletswhose outer layers consist of 100 mg and 150 mg of thegranulate described in point 8 B and correspondingrespectively to a thickness of about 1.7 m for one ofthem and 2.7 mm for the other. The inner layer iscomposed of 100 mg of granulate containing the activesubstance (equivalent to 10.0 mg of alfuzosinhydrochloride). By working according to the abovedescription in point 7 C, three-layer tablets having anaverage weight of 350 mg and containing 10.0 mg ofalfuzosin hydrochloride are produced.. _..........-u10152025CA 02264250 l999-02- 1938Exam 1e 9Preparation of a series of tablets (5000) based onalfuzosin hydrochloride.g_A: Preparation of the granulate containing the activesubstanceA granulate is prepared, which is used in thepreparation of layer 2 of Figure 1, containing 15 mg ofalfuzosin hydrochloride, with a composition identicalto that described in Example 7 A and according to thesame PIOCESS .g_§: Preparation of the granulate constituting layers 1and 3 which swell and form a barrierAn amount of granulate required to obtain10,000 layers which swell and form a barrier, layers 1and 3 of Figure 1, is prepared, each layercorresponding to the composition and to themanufacturing process described in Example 8 B.2_Q: Preparation of the three-layer tablets (bycompression)By working in the manner described above(Example 8 C), three-layer tablets containing 15.0 mgof active substance and having an average weight of350 mg are obtained with 100 mg of granulate describedin Example 9 A and, for the outer layers, 100 and150 mg of granulate described in point 9 B101520. .- ..c.........â---.1-2â-nu-.--»«-~CA 02264250 l999-02- 1939corresponding respectively to a thickness of about1.8 mm for one and 2.7 mm for the other.Example 10Preparation of a series of tablets (5000) based onalfuzosin hydrochloride. 10 A: Preparation of the granulate containing theactive substanceA granulate is prepared, which is used in thepreparation of layer 2 of Figure 1, containing 7.5 mgof alfuzosin hydrochloride, with a composition which isidentical to that described in Example 2 A andaccording to the same process.10 B: Preparation of the granulate constituting layers1 and 3 which swell and form a barrierAn amount of granulate required to obtain10,000 layers which swell and form a barrier, layers 1and 3 of Figure 1, is prepared, each layercorresponding to the composition and to themanufacturing process described in Example 4 B.10 C: Preparation of the three-layer tablets (bycompression)By working in the manner described above(Example 8 C), three-layer tablets containing 7.5 mg ofactive substance and having an average weight of 350 mg. .........â..â-.u..g--u-âau.......W.101520CA 02264250 l999-02- 1940are obtained, with 100 mg of granulate described inExample 10 A and, for the outer layers, 100 and 150 mgof granulate described in point 10 B, correspondingrespectively to a thickness of about 1.8 mm for one and2.7 mm for the other.Example 11Preparation of a series of tablets (5000) based onalfuzosin hydrochloride.11 A: Preparation of the granulate containing theactive substanceA granulate containing 10 mg of alfuzosinhydrochloride is prepared, with a composition which isidentical to that described in Example 4 A andaccording to the same process.11 B: Preparation of the granulate constituting layer 1which swellsAn amount of granulate required to obtain10,000 layers which swell is prepared. Each layercorresponds to the composition and to the manufacturingprocess described in Example 4 B.11 C: Preparation of the twoâlayer tablets (bycompression)By working in the manner described above(Example 8 C), the granulates obtained, 100 mg ofCA 02264250 l999-02- 1941granulate described in Example 10 A and, for the outerlayer, 150 mg of granulate described in point 10 B, areloaded into two supply hoppers of a rotary multiâlayerpress capable of producing twoâlayer tablets.
Claims (24)
1. Pharmaceutical tablet intended for the oral route, for the controlled release of alfuzosin hydrochloride into the proximal segments of the gastrointestinal tract, this tablet being characterized in that it consists of:
a) a first layer having the property of swelling 1.5 times relative to the initial volume after 2 hours on contact with aqueous biological fluids, the layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers constituting from 5.0 to 90%
of the weight of the layer, b) a second layer adjacent to the first layer, in which the alfuzosin hydrochloride is conveyed, this layer being formulated with hydrophilic polymers and with other auxiliary substances, in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period, c) and optionally a third layer obtained by compression and applied to the second layer, comprising hydrophilic polymers which are chosen from the group consisting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose having a molecular weight of from 1,000 to 4,000,000, hydroxypropylcellulose having a molecular weight of from 2,000 to 2,000,000, carboxyvinyl polymers, chitosans, mannans, galactomannans, xanthans, carrageenans, amylose, alginic acid, its salts and its derivatives, pectins, acrylates, methacrylates, acrylic /methacrylic copolymers, polyanhydrides, polyamino acids, poly (methyl vinyl ether/maleic anhydride) polymers, polyvinyl alcohols, glucans, scleroglucans, carboxymethylcellulose, ethylcellulose and methylcellulose.
a) a first layer having the property of swelling 1.5 times relative to the initial volume after 2 hours on contact with aqueous biological fluids, the layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers constituting from 5.0 to 90%
of the weight of the layer, b) a second layer adjacent to the first layer, in which the alfuzosin hydrochloride is conveyed, this layer being formulated with hydrophilic polymers and with other auxiliary substances, in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period, c) and optionally a third layer obtained by compression and applied to the second layer, comprising hydrophilic polymers which are chosen from the group consisting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose having a molecular weight of from 1,000 to 4,000,000, hydroxypropylcellulose having a molecular weight of from 2,000 to 2,000,000, carboxyvinyl polymers, chitosans, mannans, galactomannans, xanthans, carrageenans, amylose, alginic acid, its salts and its derivatives, pectins, acrylates, methacrylates, acrylic /methacrylic copolymers, polyanhydrides, polyamino acids, poly (methyl vinyl ether/maleic anhydride) polymers, polyvinyl alcohols, glucans, scleroglucans, carboxymethylcellulose, ethylcellulose and methylcellulose.
2. Tablet according to Claim 1, characterized in that in order to promote rapid swelling, at least one of the layers consists of hydrophilic excipients, which are chosen from the group consisting of super "disintegrating"
excipients comprising crosslinked polyvinylpyrrolidone, hydroxypropylcellulose and hydroxypropylmethylcellulose having a molecular weight of 1,000 to 1,000,000 crosslinked sodium carboxymethylcellulose, carboxymethyl starch and its salts, and divinylbenzene/potassium methacrylate copolymer.
excipients comprising crosslinked polyvinylpyrrolidone, hydroxypropylcellulose and hydroxypropylmethylcellulose having a molecular weight of 1,000 to 1,000,000 crosslinked sodium carboxymethylcellulose, carboxymethyl starch and its salts, and divinylbenzene/potassium methacrylate copolymer.
3. Tablet according to Claim 2, characterized in that the hydrophilic excipients constitute from 1 to 50% of the weight of the layer.
4. Tablet according to any one of Claims 1 to 3, characterized in that the third layer has an identical composition to that of the first layer and the same functional properties.
5. Tablet according to Claim 4, characterized in that the first and third layers differ in the amount applied to the second layer and their thickness.
6. Tablet according to Claim 1, characterized in that the second layer containing the active substance consists of 5 to 90% by weight of hydrophilic polymers.
7. Tablet according to any one of Claims 1 to 6, characterized in that the third layer further contains alfuzosin hydrochloride.
8. Tablet according to any one of Claims 1 to 7, characterized in that the amount of alfuzosin hydrochloride carried in the tablet ranges from 2.5 to 50 mg.
9. Tablet according to any one of Claims 1 to 8, further comprising surfactants selected from the group consisting of sodium lauryl sulphate, sodium ricinoleate, sodium tetradecyl sulphate, sodium dioctyl sulphosuccinate, cetomacrogol, poloxamer, glyceryl monostearate, polysorbates, sorbitan monolaurate and lecithins, are used in order to promote rapid swelling of one of the layers.
10. Tablet according to any one of Claims 1 to 9, further comprising hydrophilic diluents selected from the group consisting of mannitol, lactose, starches of various origins, sorbitol, xylitol, microcrystalline cellulose and/or substances which are used in order to promote the penetration of water and/or aqueous fluids into the various layers.
11. Tablet according to any one of Claims 1 to 10, further comprising hydrophobic diluents selected from the group consisting of glyceryl monostearate, palmitates, hydrogenated plant oils, waxes, mono-, di- or trisubstituted glycerides are used for slowing down the penetration of water and/or of aqueous fluids into the second layer containing the active substance and into the first and third layers.
12. Tablet according to any one of Claims 1 to 11, characterized in that the various layers of the tablet have independently from each other thicknesses ranging from 0.2 mm to 8 mm.
13. Tablet according to any one of Claims 1 to 12, characterized in that the pressure applied in order to obtain the tablet ranges from 7 to 50 KN.
14. Tablet according to any one of Claims 1 to 13, characterized in that it is covered with a coating which may contain alfuzosin hydrochloride.
15. Pharmaceutical composition comprising one or more tablets according to any one of Claims 1 to 14.
16. Tablet according to Claim 1 wherein the hydrophilic polymers of the first layer constitute from 10 to 85% of the weight of the layer.
17. Tablet according to Claim 2, characterized in that the hydrophilic excipients constitute from 10 to 30% of the weight of the layer.
18. Tablet according to any one of Claims 1 to 5, characterized in that, on contact with aqueous liquids, at least one of the layers of the tablet increases by at least 3 times relative to the initial volume, after two hours.
19. Tablet according to Claim 1, characterized in that the second layer containing the active substance consists of 10 to 85% by weight of hydrophilic polymers.
20. Tablet according to any one of Claims 1 to 11, characterized in that the various layers of the tablet have independently from each other thicknesses ranging from 1 mm to 4 mm.
21. Tablet according to Claim 1, characterized in that:
a) the first layer has the following percentage composition:
Hydroxypropylmethylcellulose 79.75%
Hydrogenated castor oil 13.50%
Yellow iron oxide 0.25%
Silica gel 0.50%
b) the second layer has the following unit composition:
Alfuzosin hydrochloride 10.00 mg Mannitol 10.00 mg Hydroxypropylmethylcellulose USP 2208 10.00 mg Polyvinylpyrrolidone 3.20 mg Microcrystalline cellulose 65.00 mg Magnesium stearate 1.00 mg Colloidal silica 1.25 mg and c) the third layer has the following percentage composition:
Hydroxypropylmethylcellulose 76.00%
Hydrogenated castor oil 18.60%
Polyvinylpyrrolidone 3.15%
Yellow iron oxide 0.10%
Magnesium stearate 0.70%
Colloidal silica 1.45%
a) the first layer has the following percentage composition:
Hydroxypropylmethylcellulose 79.75%
Hydrogenated castor oil 13.50%
Yellow iron oxide 0.25%
Silica gel 0.50%
b) the second layer has the following unit composition:
Alfuzosin hydrochloride 10.00 mg Mannitol 10.00 mg Hydroxypropylmethylcellulose USP 2208 10.00 mg Polyvinylpyrrolidone 3.20 mg Microcrystalline cellulose 65.00 mg Magnesium stearate 1.00 mg Colloidal silica 1.25 mg and c) the third layer has the following percentage composition:
Hydroxypropylmethylcellulose 76.00%
Hydrogenated castor oil 18.60%
Polyvinylpyrrolidone 3.15%
Yellow iron oxide 0.10%
Magnesium stearate 0.70%
Colloidal silica 1.45%
22. Tablet according to Claim 21, characterized in that the first layer has the following percentage composition:
Hyrdroxypropylmethylcellulose 75.00%
Glyceryl behenate 13.40%
Polyvinylpyrrolidone 5.00%
Iron oxide 0.10%
Polyvinylpyrrolidone 5.00%
Magnesium stearate 1.00%
Colloidal silica 0.50%.
Hyrdroxypropylmethylcellulose 75.00%
Glyceryl behenate 13.40%
Polyvinylpyrrolidone 5.00%
Iron oxide 0.10%
Polyvinylpyrrolidone 5.00%
Magnesium stearate 1.00%
Colloidal silica 0.50%.
23. Tablet according to Claim 1, characterized in that:
the first layer and third layer have following the percentage composition:
Hydroxypropylmethylcellulose USP 2208 40.00%
Lactose 39.75%
Glyceryl behenate 13.50%
Yellow iron oxide 0.25%
Polyvinylpyrrolidone 5.00%
Magnesium stearate 1.00$
Colloidal silica 0.50%
and the second layer has the following unit composition:
Alfuzosin hydrochloride 10.00 mg Lactose 60.30 mg Hydroxypropylmethylcellulose USP 2208 25.00 mg Polyvinylpyrrolidone 3.20 mg Magnesium stearate 1.00 mg Colloidal silica 0.50 mg.
the first layer and third layer have following the percentage composition:
Hydroxypropylmethylcellulose USP 2208 40.00%
Lactose 39.75%
Glyceryl behenate 13.50%
Yellow iron oxide 0.25%
Polyvinylpyrrolidone 5.00%
Magnesium stearate 1.00$
Colloidal silica 0.50%
and the second layer has the following unit composition:
Alfuzosin hydrochloride 10.00 mg Lactose 60.30 mg Hydroxypropylmethylcellulose USP 2208 25.00 mg Polyvinylpyrrolidone 3.20 mg Magnesium stearate 1.00 mg Colloidal silica 0.50 mg.
24. Tablet according to Claim 23, characterized in that the second layer has the following unit composition:
Alfuzosin hydrochloride 15.00 mg Lactose 55.30 mg Hydroxypropylmethylcellulose USP 2208 25.00 mg Polyvinylpyrrolidone 3.20 mg Magnesium stearate 1.00 mg Colloidal silica 0.50 mg.
Alfuzosin hydrochloride 15.00 mg Lactose 55.30 mg Hydroxypropylmethylcellulose USP 2208 25.00 mg Polyvinylpyrrolidone 3.20 mg Magnesium stearate 1.00 mg Colloidal silica 0.50 mg.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9610551A FR2752737B1 (en) | 1996-08-29 | 1996-08-29 | CONTROLLED RELEASE TABLET OF ALFUZOSINE HYDROCHLORIDE |
| FR96/10551 | 1996-08-29 | ||
| FR9704386 | 1997-04-10 | ||
| FR97/04386 | 1997-04-10 | ||
| PCT/FR1997/001515 WO1998008515A1 (en) | 1996-08-29 | 1997-08-22 | Tablet with controlled release of alfuzosine chlorydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2264250A1 CA2264250A1 (en) | 1998-03-05 |
| CA2264250C true CA2264250C (en) | 2005-07-05 |
Family
ID=26232935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002264250A Expired - Lifetime CA2264250C (en) | 1996-08-29 | 1997-08-22 | Tablet with controlled release of alfuzosin hydrochloride |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US6149940A (en) |
| EP (1) | EP0938318B1 (en) |
| JP (1) | JP3797388B2 (en) |
| KR (1) | KR100364328B1 (en) |
| CN (2) | CN100335057C (en) |
| AP (1) | AP1107A (en) |
| AR (1) | AR009312A1 (en) |
| AT (1) | ATE200864T1 (en) |
| AU (1) | AU724490B2 (en) |
| BG (1) | BG63768B1 (en) |
| BR (1) | BR9713237B1 (en) |
| CA (1) | CA2264250C (en) |
| CO (1) | CO4920217A1 (en) |
| CY (1) | CY2284B1 (en) |
| CZ (1) | CZ295066B6 (en) |
| DE (1) | DE69704712T2 (en) |
| DK (1) | DK0938318T3 (en) |
| EE (1) | EE03855B1 (en) |
| ES (1) | ES2159400T3 (en) |
| GR (1) | GR3036291T3 (en) |
| HK (1) | HK1020875A1 (en) |
| HU (1) | HU228007B1 (en) |
| IL (1) | IL128146A (en) |
| IS (1) | IS2091B (en) |
| MX (1) | MXPA99001958A (en) |
| NO (1) | NO326206B1 (en) |
| NZ (1) | NZ334018A (en) |
| OA (1) | OA10983A (en) |
| PL (1) | PL191546B1 (en) |
| PT (1) | PT938318E (en) |
| RU (1) | RU2183459C2 (en) |
| SI (1) | SI0938318T1 (en) |
| SK (1) | SK284388B6 (en) |
| TR (1) | TR199900289T2 (en) |
| TW (1) | TW522023B (en) |
| UA (1) | UA69374C2 (en) |
| WO (1) | WO1998008515A1 (en) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6720471B1 (en) | 1998-04-28 | 2004-04-13 | The Procter & Gamble Company | Absorbent articles having reduced rewet with distribution materials positioned underneath storage material |
| US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
| FR2784583B1 (en) * | 1998-10-16 | 2002-01-25 | Synthelabo | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE |
| JP2003521507A (en) | 2000-02-04 | 2003-07-15 | ディポメド，インコーポレイティド | Shell-core dosage form approaching zero order drug release |
| AR030557A1 (en) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD |
| FR2820318B1 (en) * | 2001-02-08 | 2005-12-23 | Ellipse Pharmaceuticals | METHOD FOR MANUFACTURING A FLOATING COMPRESSOR INCLUDING AN ACTIVE INGREDIENT AND A COMPRESS OBTAINED |
| FR2820319B3 (en) * | 2001-02-08 | 2003-12-05 | Ellipse Pharmaceuticals | PROCESS FOR PRODUCING A FLOATING TABLET INCLUDING ALFUZOSINE AND TABLET OBTAINED |
| US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| US7163696B2 (en) * | 2001-10-11 | 2007-01-16 | Pfizer Inc. | Pharmaceutical formulations |
| US7309444B2 (en) * | 2002-08-29 | 2007-12-18 | Stellar Technology Company | Layered tablet water treatment compositions and method of use |
| US6852238B2 (en) * | 2002-08-29 | 2005-02-08 | Steller Technology Company | Layered tablet water treatment compositions and method of use |
| EP1551372B8 (en) | 2002-09-20 | 2018-08-01 | Alpharma Pharmaceuticals LLC | Sequestering subunit and related compositions and methods |
| MXPA05004338A (en) * | 2002-10-22 | 2005-06-22 | Ranbaxy Lab Ltd | Sustained release compositions containing alfuzosin. |
| CN1993112A (en) * | 2004-07-29 | 2007-07-04 | 赛诺菲-安万特 | Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility |
| FR2874325B1 (en) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN |
| US20060062845A1 (en) * | 2004-09-17 | 2006-03-23 | Cimex Pharma Ag | Alfuzosin tablets and synthesis |
| US20060062846A1 (en) * | 2004-09-17 | 2006-03-23 | Cimex Pharma Ag | Alfuzosin tablets and synthesis |
| ITMI20050391A1 (en) * | 2005-03-11 | 2006-09-12 | Ph & T S P A | CONTROLLED RELEASE FORMULATIONS OF ALFUZOSIN |
| US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
| US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
| DK1889198T3 (en) | 2005-04-28 | 2015-02-09 | Proteus Digital Health Inc | Pharma-informatics system |
| US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
| US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
| BRPI0611535B1 (en) | 2005-05-05 | 2021-11-30 | Sensient Flavors Inc | METHOD FOR PROCESSING YEAST CELLS TO PRODUCE BETA-GLUCANS AND MANANAS |
| US20070185232A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
| US20070185235A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive compositions |
| US20070185237A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
| US20090238776A1 (en) * | 2005-11-09 | 2009-09-24 | Arif Ali Baig | Oral Care Compositions and Methods |
| US20070185236A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive compositions |
| US7834066B2 (en) * | 2005-11-09 | 2010-11-16 | The Procter & Gamble Company | Denture adhesive articles |
| US20070185233A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
| US20070129460A1 (en) * | 2005-11-09 | 2007-06-07 | Jayanth Rajaiah | Denture adhesive articles |
| US8206742B2 (en) * | 2006-01-12 | 2012-06-26 | Wockhardt Ltd. | Sustained release compositions of alfuzosin |
| CA2650920C (en) | 2006-05-02 | 2016-10-18 | Proteus Biomedical, Inc. | Patient customized therapeutic regimens |
| EP2526932B1 (en) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition |
| US20080003286A1 (en) * | 2006-06-29 | 2008-01-03 | Sathya Narayana Vemula | Sustained delivery alfuzosin compositions |
| US20080181947A1 (en) * | 2006-09-26 | 2008-07-31 | Astellas Pharma Inc. | Controlled release dosage form of tacrolimus |
| US20080095844A1 (en) * | 2006-10-23 | 2008-04-24 | Rajhans Sujay Kamalakar | Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof |
| SG175681A1 (en) | 2006-10-25 | 2011-11-28 | Proteus Biomedical Inc | Controlled activation ingestible identifier |
| EP2069004A4 (en) | 2006-11-20 | 2014-07-09 | Proteus Digital Health Inc | Active signal processing personal health signal receivers |
| US20080138412A1 (en) * | 2006-12-06 | 2008-06-12 | Fu-Yung Lin | Sustained release alfuzosin hydrochl formulation and method for their production |
| US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
| WO2008073388A2 (en) * | 2006-12-11 | 2008-06-19 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making and methods of use |
| EP2119442A4 (en) | 2006-12-28 | 2010-12-15 | Astellas Pharma Inc | Tacrolimus sustained release pharmaceutical composition |
| MY165532A (en) | 2007-02-01 | 2018-04-02 | Proteus Digital Health Inc | Ingestible event marker systems |
| AU2008216170B2 (en) | 2007-02-14 | 2012-07-26 | Otsuka Pharmaceutical Co., Ltd. | In-body power source having high surface area electrode |
| WO2008102235A1 (en) * | 2007-02-20 | 2008-08-28 | Aurobindo Pharma Limited | Controlled release formulations of alfuzosin |
| US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
| WO2008112577A1 (en) | 2007-03-09 | 2008-09-18 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
| US8115618B2 (en) | 2007-05-24 | 2012-02-14 | Proteus Biomedical, Inc. | RFID antenna for in-body device |
| PT2192946T (en) | 2007-09-25 | 2022-11-17 | Otsuka Pharma Co Ltd | In-body device with virtual dipole signal amplification |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| ES2840773T3 (en) | 2008-03-05 | 2021-07-07 | Otsuka Pharma Co Ltd | Multimode Communication Ingestible Event Markers and Systems |
| JP5373069B2 (en) * | 2008-06-04 | 2013-12-18 | ザ プロクター アンド ギャンブル カンパニー | Denture adhesive composition and method |
| CN102159134B (en) | 2008-07-08 | 2015-05-27 | 普罗透斯数字保健公司 | Ingestible event marker data framework |
| WO2010019778A2 (en) | 2008-08-13 | 2010-02-18 | Proteus Biomedical, Inc. | Ingestible circuitry |
| US20100233259A1 (en) * | 2008-12-12 | 2010-09-16 | Pascal Grenier | Dosage form of ropinirole |
| CA2750158A1 (en) | 2009-01-06 | 2010-07-15 | Proteus Biomedical, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
| TWI544917B (en) | 2009-01-06 | 2016-08-11 | 波提亞斯數位康健公司 | Pharmaceutical dosages delivery system |
| US20100183717A1 (en) * | 2009-01-16 | 2010-07-22 | Kristin Arnold | Controlled-release formulations |
| GB2480965B (en) | 2009-03-25 | 2014-10-08 | Proteus Digital Health Inc | Probablistic pharmacokinetic and pharmacodynamic modeling |
| MX2011011506A (en) | 2009-04-28 | 2012-05-08 | Proteus Biomedical Inc | Highly reliable ingestible event markers and methods for using the same. |
| WO2010132331A2 (en) | 2009-05-12 | 2010-11-18 | Proteus Biomedical, Inc. | Ingestible event markers comprising an ingestible component |
| TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
| CA2790116C (en) | 2010-03-10 | 2016-02-16 | The Procter & Gamble Company | Denture adhesive compositions |
| PT2554168T (en) | 2010-03-29 | 2018-02-28 | Astellas Pharma Inc | Controlled release pharmaceutical composition |
| US9597487B2 (en) | 2010-04-07 | 2017-03-21 | Proteus Digital Health, Inc. | Miniature ingestible device |
| WO2011124953A2 (en) * | 2010-04-07 | 2011-10-13 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| TWI557672B (en) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
| JP2014504902A (en) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス， インコーポレイテッド | Ingestible device with medicinal product |
| CN102475690B (en) * | 2010-11-30 | 2016-06-01 | 安国药品株式会社 | Include the slow releasing tablet of alfuzosin hydrochloride |
| WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| CN103827914A (en) | 2011-07-21 | 2014-05-28 | 普罗秋斯数字健康公司 | Mobile communication device, system, and method |
| US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
| CN104487347B (en) | 2012-07-23 | 2017-09-01 | 普罗秋斯数字健康公司 | Method and system for manufacturing the tablet for including electronic device |
| AU2013331417B2 (en) | 2012-10-18 | 2016-06-02 | Proteus Digital Health, Inc. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
| TWI659994B (en) * | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | Highly-swellable polymeric films and compositions comprising the same |
| WO2014144738A1 (en) | 2013-03-15 | 2014-09-18 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
| EP3968263A1 (en) | 2013-06-04 | 2022-03-16 | Otsuka Pharmaceutical Co., Ltd. | System, apparatus and methods for data collection and assessing outcomes |
| US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
| US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
| US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
| WO2017078557A1 (en) * | 2015-11-05 | 2017-05-11 | Анатолий Викторович ЗАЗУЛЯ | Preparing a tablet with a mechanism for enhancing the therapeutic effectiveness of a drug using a nano-dose of an analogue |
| CN111493872B (en) | 2016-07-22 | 2023-05-05 | 大冢制药株式会社 | Electromagnetic sensing and detection of ingestible event markers |
| US10820831B2 (en) | 2016-10-26 | 2020-11-03 | Proteus Digital Health, Inc. | Methods for manufacturing capsules with ingestible event markers |
| CN114209668B (en) * | 2022-01-13 | 2023-01-31 | 山东新时代药业有限公司 | Alfuzosin hydrochloride sustained release preparation and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2582513B1 (en) * | 1985-05-28 | 1988-08-05 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING ALFUZOSINE |
| IT1188212B (en) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES |
| IT1237904B (en) * | 1989-12-14 | 1993-06-18 | Ubaldo Conte | CONTROLLED SPEED RELEASE TABS OF ACTIVE SUBSTANCES |
| GB9311191D0 (en) * | 1993-05-29 | 1993-07-14 | Danbiosyst Uk | Controlled release drug formulation |
| FR2717388B1 (en) * | 1994-03-21 | 1996-11-22 | Synthelabo | Extended release dosage forms of alfuzosin hydrochloride. |
-
1997
- 1997-08-22 TR TR1999/00289T patent/TR199900289T2/en unknown
- 1997-08-22 CN CNB2004100422955A patent/CN100335057C/en not_active Expired - Lifetime
- 1997-08-22 PT PT97937651T patent/PT938318E/en unknown
- 1997-08-22 NZ NZ334018A patent/NZ334018A/en not_active IP Right Cessation
- 1997-08-22 RU RU99105730/14A patent/RU2183459C2/en active
- 1997-08-22 EE EEP199900090A patent/EE03855B1/en unknown
- 1997-08-22 CA CA002264250A patent/CA2264250C/en not_active Expired - Lifetime
- 1997-08-22 US US09/147,581 patent/US6149940A/en not_active Expired - Lifetime
- 1997-08-22 AU AU40201/97A patent/AU724490B2/en not_active Expired
- 1997-08-22 AT AT97937651T patent/ATE200864T1/en active
- 1997-08-22 UA UA99020755A patent/UA69374C2/en unknown
- 1997-08-22 KR KR1019997001666A patent/KR100364328B1/en not_active IP Right Cessation
- 1997-08-22 DK DK97937651T patent/DK0938318T3/en active
- 1997-08-22 CN CNB971975582A patent/CN1155382C/en not_active Expired - Lifetime
- 1997-08-22 PL PL331862A patent/PL191546B1/en unknown
- 1997-08-22 MX MXPA99001958A patent/MXPA99001958A/en active IP Right Grant
- 1997-08-22 CZ CZ1999655A patent/CZ295066B6/en not_active IP Right Cessation
- 1997-08-22 BR BRPI9713237-3A patent/BR9713237B1/en not_active IP Right Cessation
- 1997-08-22 EP EP97937651A patent/EP0938318B1/en not_active Expired - Lifetime
- 1997-08-22 JP JP51133198A patent/JP3797388B2/en not_active Expired - Lifetime
- 1997-08-22 HU HU9903428A patent/HU228007B1/en unknown
- 1997-08-22 AP APAP/P/1999/001470A patent/AP1107A/en active
- 1997-08-22 SK SK270-99A patent/SK284388B6/en not_active IP Right Cessation
- 1997-08-22 ES ES97937651T patent/ES2159400T3/en not_active Expired - Lifetime
- 1997-08-22 IL IL12814697A patent/IL128146A/en not_active IP Right Cessation
- 1997-08-22 DE DE69704712T patent/DE69704712T2/en not_active Expired - Lifetime
- 1997-08-22 SI SI9730158T patent/SI0938318T1/en unknown
- 1997-08-22 WO PCT/FR1997/001515 patent/WO1998008515A1/en active IP Right Grant
- 1997-08-25 AR ARP970103839A patent/AR009312A1/en active IP Right Grant
- 1997-08-26 TW TW086112274A patent/TW522023B/en not_active IP Right Cessation
- 1997-08-28 CO CO97049830A patent/CO4920217A1/en unknown
-
1999
- 1999-01-29 IS IS4964A patent/IS2091B/en unknown
- 1999-02-01 BG BG103138A patent/BG63768B1/en unknown
- 1999-02-26 OA OA9900042A patent/OA10983A/en unknown
- 1999-02-26 NO NO19990944A patent/NO326206B1/en not_active IP Right Cessation
- 1999-12-20 HK HK99105968A patent/HK1020875A1/en not_active IP Right Cessation
-
2001
- 2001-07-26 GR GR20010401141T patent/GR3036291T3/en unknown
-
2002
- 2002-05-15 CY CY0200038A patent/CY2284B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2264250C (en) | Tablet with controlled release of alfuzosin hydrochloride | |
| KR100618234B1 (en) | Dosage forms comprising porous particles | |
| AU719170B2 (en) | Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids | |
| AU596183B2 (en) | Controlled release bases for pharmaceuticals | |
| US20090124702A1 (en) | Pharmaceutical Compositions of Metformin | |
| US20140294953A1 (en) | Abuse-Resistant Formulations | |
| US3148124A (en) | Method of preparing sustained release pharmaceutical tablets | |
| WO1997047285A1 (en) | Gastric-retentive oral controlled drug delivery system with enhanced retention properties | |
| HU202101B (en) | Process for producing retarde peroral pharmaceutical composition | |
| JP2006520390A (en) | Method for producing sustained-release tablets | |
| DE10014588A1 (en) | Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone | |
| JP2008509193A (en) | Sustained release pellet preparation containing pramipexole or a pharmaceutically acceptable salt thereof, its production method and use | |
| US20100092554A1 (en) | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | |
| WO2002024203A2 (en) | Controlled release formulations for oral administration | |
| WO2005046648A1 (en) | Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine | |
| WO2004037228A1 (en) | Sustained release compositions containing alfuzosin | |
| JPS61286330A (en) | Slow-releasing medicinal preparation for oral administration | |
| US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
| CN101623289A (en) | Novel drospirenone analogue medicinal composition | |
| CN101623290A (en) | Drospirenone analogue medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170822 |